Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | $6.00 | Market Perform → Outperform | Leerink Partners |
| 2/24/2025 | $12.00 | Buy | Guggenheim |
| 2/19/2025 | $12.00 | Overweight | Piper Sandler |
| 12/23/2024 | $32.00 | Buy | D. Boral Capital |
| 11/15/2024 | $5.00 → $4.00 | Outperform → Market Perform | Leerink Partners |
| 9/16/2024 | $5.00 | Neutral → Buy | Ladenburg Thalmann |
| 1/31/2023 | $8.00 | Buy | Jefferies |
| 1/27/2023 | $9.00 | Buy | Stifel |
SCHEDULE 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)
144 - Compass Therapeutics, Inc. (0001738021) (Subject)
144 - Compass Therapeutics, Inc. (0001738021) (Subject)
Leerink Partners upgraded Compass Therapeutics from Market Perform to Outperform and set a new price target of $6.00
Guggenheim initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $12.00
Piper Sandler initiated coverage of Compass Therapeutics with a rating of Overweight and set a new price target of $12.00
Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion. Webinar Details: Date: May 04, 2022 Time: 8:00 a.m. ET Webcast: Registration Link Replay availability: A replay will be available on the Compass website for 6 months. Abo
NEW YORK, July 20, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter 2021 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index. The OTCQX Composite Index (.OTCQX), a benchmark for the overall OTCQX Best Market, was up 3.9% in the second quarter. Ninety-two new companies were added to the index, including: AirBoss of America Corp. (OTCQX:ABSSF); Blackrock Silver Corp. (OTCQX:BKRRF); Belo Sun Mining Corp. (OTCQX:BSXGF); Caldwell Partners International Inc. (OTCQX:CWLPF); Graphite One Inc. (OTCQX:GPHOF)
BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (BTC). The IST is being conducted at The University of Texas MD Anderson Cancer Center. "This first-line study of tovecimig in patients with BTC represents a significant step forward and we are deeply grateful to the dedicated team at MD Anderson for their lea
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025. Presentation Details Date: Tuesday, April 8, 2025 Time: 3:00 PM EDTWebcast Link: https://wsw.com/webcast/stifel99/cmpx/2119000 Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass' Events page. About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmac
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.The study also showed differences between treatment arms for other efficacy measures, including progressive disease (PD) rates of 16.2% in patients on tovecimig in combination with paclitaxel versus 42.1
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. "We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "We have severa
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC). Initial data expected in the third quarter of 2023Presented results of a Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers SymposiumExpanded the management team with the appointment of Minori Rosales, M.D. PhD, as Senior Vice President & Head of Clinical DevelopmentAppointed Richard Lindahl, M.B.A., EVP & CFO of Emergent BioSolutio
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)